Phase III SQUIRE Trial in Patients With NSCLC Treated With Necitumumab

At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

New results from the phase 2 APPLE trial shows how the use of osimertinib in the upfront setting compares with combination therapy in patients with EGFR-positive non–small cell lung caner.

Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.

In an interview, Krisda Chaiyachati, MD, MPH, discussed some of the social determinants of health for patients with cancer and some of the challenges patients undergoing treatment face, including transportation insecurity.

In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.